Clozapine-A dangerous drug in a clozapine-naïve subject

Forensic Science International

Volumn 214, Issue 1-3, 2012, Pages

  Stanworth, D ^a   Hunt, N C A ^b   Flanagan, R J ^c  

^a LGC   (United Kingdom)

^b F5 Culham Science Center   (United Kingdom)

^c KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Clozapine toxicity: na ve subjects; Clozapine: post mortem toxicology; Clozapine: sudden death

Indexed keywords

BECLOMETASONE DIPROPIONATE; CHLORHEXIDINE; CLOZAPINE; FERROUS SULFATE; OLANZAPINE; OMEPRAZOLE; SALBUTAMOL; SERTRALINE;

ADULT; ARTICLE; AUTOPSY; BLOOD ANALYSIS; CARDIOMEGALY; CARDIOPULMONARY INSUFFICIENCY; CASE REPORT; DRUG BLOOD LEVEL; DRUG FATALITY; FORENSIC TOXICOLOGY; HEART LEFT VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER HYPERTROPHY; MALE; MENTAL DISEASE; NONALCOHOLIC FATTY LIVER; OBESITY; PRESCRIPTION; PRIORITY JOURNAL;

EID: 84855208098     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2011.07.032     Document Type: Article

References (13)

1. Kane J.M., Correll C.U. Pharmacologic treatment of schizophrenia. Dialogues Clin. Neurosci. 2010, 12:345-357.
2. Flanagan R.J., Dunk L. Haematological toxicity of drugs used in psychiatry. Hum. Psychopharmacol. 2008, 23(S1):S27-S41.
3. Pokorny R., Finkel M.J., Robinson W.T. Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine. Pharm. Res. 1994, 11:1221.
4. Havnen G.C., Beck L.I.F., Lindqvist R. A dose as low as 100mg of clozapine can lead to severe toxicity in clozapine-naive individuals. Clin. Toxicol. 2009, 47:436-510.
5. Palmiere C., Mangin P. Erroneous administration of clozapine in a very elderly patient. J. Clin. Psychopharmacol. 2011, 31:122-123.
6. Trenton A., Currier G., Zwemer F. Fatalities associated with therapeutic use and overdose of atypical antipsychotics. CNS Drugs 2003, 17:307-324.
7. Flanagan R.J. Fatal toxicity of drugs used in psychiatry. Hum. Psychopharmacol. 2008, 23(S1):S43-S51.
8. Cormac I., Brown A., Creasey S., Ferriter M., Huckstep B. A retrospective evaluation of the impact of total smoking cessation on psychiatric inpatients taking clozapine. Acta Psychiatr. Scand. 2010, 121:393-397.
9. Flanagan R.J., Spencer E.P., Morgan P.E., Barnes T.R.E., Dunk L. Suspected clozapine poisoning in the UK/Eire, 1992-2003. Forensic Sci. Int. 2005, 155:91-99.
10. Flanagan R.J., Ball R.Y. Gastrointestinal hypomotility: an under-recognised life-threatening adverse effect of clozapine. Forensic Sci. Int. 2011, 206:e31-e36.
11. Couchman L., Morgan P.E., Spencer E.P., Flanagan R.J. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007. Ther. Drug Monit. 2010, 32:438-447.
12. Hiemke C., Dragicevic A., Gründer G., Hätter S., Sachse J., Vernaleken I., Müller M.J. Therapeutic monitoring of new antipsychotic drugs. Ther. Drug Monit. 2004, 26:156-160.
13. Flanagan R.J., Yusufi B., Barnes T.R. Comparability of whole-blood and plasma clozapine and norclozapine concentrations. Br. J. Clin. Pharmacol. 2003, 56:135-138.